Reacción a "EMA revises earlier decision and decides to approve lecanemab for Alzheimer's disease"

John Hardy

Professor of Neuroscience and Group Leader at the UK Dementia Research Institute, UCL.

I think this is great news and the right outcome: a restricted approval makes the most sense. In my view, this is the right outcome.

Language EN